trial

Evaluating Sublingual Dexmedetomidine For Moderate To Severe Agitation In Inpatients With Schizophrenia Or Bipolar Disorder

NCTId NCT06093451
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 4 · Unknown
Enrollment 32 (estimated)
Sponsored by Temple University Collaborative on Community Inclusion
Primary completion 2024-07-01
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 4
Status
Unknown
Enrollment
32 (estimated)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
None
Start
2023-07-01
Primary completion
2024-07-01
Eligibility
ALL · 18 Years · 55 Years

Interventions & indications

Drugs
DexmedetomidineLorazepam 2 MG/ML

Sponsors

Temple University Collaborative on Community InclusionLead Sponsor
BioXcel Therapeutics IncCollaborator

Sites

1 total
Philadelphia, United States

Facts & assertions

4 sourced
Enrollment
32
Phase
PHASE4
Primary Completion Date
2024-07-01
Status
UNKNOWN
relationships
The graph out of here
drug
Dexmedetomidine
drug
Lorazepam 2 MG/ML
drug
lead_sponsor
Temple University Collaborative on Community Inclusion
company
collaborator
BioXcel Therapeutics Inc
company
indication
Schizo Affective Disorder
indication
Bipolar Disorder
indication
Psychomotor Agitation
indication